Btg Dividends - BTG

Btg Dividends - BTG

Best deals to access real time data!
Monthly Subscription
for only
Level 2 Basic
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Btg Plc BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 840.00 00:00:00
Open Price Low Price High Price Close Price Previous Close
840.00 840.00
more quote information »
Industry Sector

Btg BTG Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

bargainbob: Merry Christmas all ex holders, anyone heard how BTG assests are performing since the merger.
dp1umb: To those still taking a look over here Just a quick warning just took a strange cold call from an Asian lady saying she is representing Boston scientific and was asking for information about my wife who the lady says was a BTG shareholder (she wasn’t they were in my name)I put the phone down on her. This seems some form of scam unless Iam missing something!!
bargainbob: 4 legs , I remember you as giving a good summary of events and belief to hold . There were not many of us around at the time following BTG. Good to hear you are doing good elsewhere with Angle.
4legs: Hello bargainbob, nice of you to remember me. Fortunately did well with BTG, despite not hanging on to the end. Very pleased to have moved BTG investment to Angle plc (AGL).
dp1umb: A very sad day for Britain as another uk listed company gets bought out by an American company just as all the signs were that BTG was to have a very successful future and us the patient shareholders were to start earning dividends. I had the same thing happen with Axis shield just as there lead product was gaining market dominance!
semper vigilans: Yes, but at least BTG were locked into the t/o before the Woodford stuff hit the fan, or BTG would have sold heavily by him as it was a liquid stock and the share price would have tanked.
spyder: Hi BB I think it is extremely unlikely that another bidder will surface until after BSX have published the Offer Document which is due by 31 January unless BSX request a second extension, but I can see no reason why this would be required. IF there was someone else interested in BTG, a bidder would want to see the full details of the BSX offer before going public with their interest, so I think that the most likely window will be between the Offer document being published and the first deadline. However, IF anyone else was interested, they will have a battle on their hands as BSX speaks very highly of BTG. Here are some interesting snippets from the Boston Scientific presentation at the JP Morgan Healthcare Conference, the CEO made the following comments about BTG: “we have Varithena coming …” “we are very excited about this company, this is one we analysed in depth for close to a year before we finally come(sic) to agreement with BTG … amazing synergies … will deliver significant shareholder value … this is an ideal, I hate to say, a perfect fit for our PI business” “it hasn’t closed yet so … upon closing the gem in that is the interventional business … Therasphere is probably the biggest gem within the entire platform … unique differentiation … China represents the largest market opportunity in the world and there are zero sales there today …. Upon closing we will be able to discuss more our plans for China but clearly there are no sales represented with BTG today and represents a significant opportunity, we have a lot of capability in that market.” “Tuck-in acquisitions … our capability in … therapeutic cancer is quite unique and we a building a sizeable business there post closing BTG” It seems clear that BSX are VERY KEEN on BTG, if only another company recognised the value there too …?
bargainbob: The parts may be greater than the sum . TIDMBTG RNS Number : 7475J Boston Scientific Corporation 07 December 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, DIRECTLY OR INDIRECTLY, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 December 2018 RECOMMENDED CASH OFFER for BTG plc ("BTG") by Bravo Bidco Limited ("Bravo Bidco") a newly incorporated entity indirectly wholly-owned by Boston Scientific Corporation ("Boston Scientific") Update on irrevocable undertaking given by Woodford Investment Management Limited ("Woodford") On 20 November 2018 the boards of Boston Scientific, Bravo Bidco and BTG announced the terms of a recommended cash offer to be made by Bravo Bidco for the entire issued and to be issued share capital of BTG at a price of 840 pence in cash per BTG Share (the "Rule 2.7 Announcement"). Defined terms in this announcement shall, except where defined in this announcement or the context requires otherwise, have the meanings given to them in the Rule 2.7 Announcement. Included in the Rule 2.7 Announcement were details of irrevocable undertakings to support the offer including that received from Woodford, which gave an irrevocable undertaking in respect of 21,253,256 BTG Shares (the "Woodford Irrevocable"). On 5 December 2018, Boston Scientific and Bravo Bidco announced that Woodford had sold: (i) 600,000 BTG Shares which were subject to the Woodford Irrevocable to Anavio Capital Partners LLP acting in its capacity as Investment Manager of Anavio Capital Event Driven UCITS Fund; and (ii) 400,000 BTG Shares which were subject to the Woodford Irrevocable to Anavio Capital Master Fund Limited, in each case in accordance with paragraph 2.2(c) of the Woodford Irrevocable. Woodford has subsequently sold 16,200,000 BTG Shares which were subject to the Woodford Irrevocable (the "Transferred Shares") to Sand Grove Capital Management LLP acting in its capacity as discretionary investment manager on behalf of Sand Grove Opportunities Master Fund Ltd, Sand Grove Tactical Fund LP and Investment Opportunities SPC for the account of Investment Opportunities 2 Segregated Portfolio ("Sand Grove"), in accordance with paragraph 2.2(c) of the Woodford Irrevocable. Therefore, Sand Grove has provided an irrevocable undertaking (the "Sand Grove Irrevocable") on substantially the same terms as the Woodford Irrevocable in respect of the Transferred Shares, save that the provisions in the Woodford Irrevocable permitting transfer of BTG Shares in circumstances, other than to the extent required by law, are not contained in the Sand Grove Irrevocable. The total number of BTG Shares which is subject to irrevocable undertakings to support the offer remains unchanged. The Sand Grove Irrevocable (as well as a copy of this announcement) will be uploaded to the Boston Scientific website (hxxp:// shortly. Enquiries: Bravo Bidco / Boston Scientific +1 (508) 683-5565 Susie Lisa (Investor Relations) Barclays Bank PLC, acting through its +44 (0) 20 7623 2323 Investment Bank (financial adviser to Bravo Bidco and Boston Scientific) Douglas Solomon Jed Brody Derek Shakespeare Barclays Bank PLC, acting through its investment bank ("Barclays"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Boston Scientific and Bravo Bidco and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than Boston Scientific and Bravo Bidco for providing the protections afforded to clients of Barclays nor for providing advice in relation to the Acquisition or any other matter referred to in this announcement. This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer, invitation, inducement or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of or exercise rights in respect of any securities, or the solicitation of any vote or approval of an offer to buy securities in any jurisdiction, pursuant to the Acquisition or otherwise nor shall there be any sale, issuance or transfer of any securities pursuant to the Acquisition in any jurisdiction in contravention of any applicable laws. The Acquisition will be implemented solely pursuant to the terms of the Scheme Document (or in the event that the Acquisition is to be implemented by means of a Takeover Offer, the Offer Document), which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Scheme. Any decision, vote or other response in respect of the Acquisition should be made only on the basis of information contained in the Scheme Document. BTG Shareholders are advised to read the formal documentation in relation to the Acquisition carefully once it has been dispatched. This announcement does not constitute a prospectus or prospectus-equivalent document. This announcement has been prepared for the purpose of complying with English law and the Code and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom. In accordance with the Code, normal United Kingdom market practice and Rule 14e-5(b) of the Exchange Act, Barclays and its affiliates will continue to act as an exempt principal trader in BTG securities on the London Stock Exchange. The purchases and activities by exempt principal traders which are required to be made public in the United Kingdom pursuant to the Code will be reported to a Regulatory Information Service and will be available on the London Stock Exchange website at This information will also be publicly disclosed in the US to the extent that such information is made public in the United Kingdom. Disclosure requirements of the Code In accordance with Rule 26.1 of the Code, a copy of this announcement will be available at hxxp://, by no later than 12 noon (London time) on 10 December 2018. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit END OUPUNVRRWBAURUA (END) Dow Jones Newswires December 07, 2018 02:00 ET (07:00 GMT)
a1ord53: BTG reaches settlement regarding CroFab® patent litigation 10 October 2014 London, UK, 10 October 2014: BTG plc (LSE: BTG) today announces that it has settled its United States patent infringement complaint against Instituto Bioclon (Bioclon) of Mexico and Rare Disease Therapeutics, Inc. (RDT) of Nashville, Tennessee. The case was filed by BTG with the International Trade Commission in October 2013 based upon the unlawful and unauthorised importation and sale into the US of certain crotalid antivenom pharmaceutical compositions that infringe one or more claims of BTG’s US Patent No. 8,048,414 (“the ‘414 patent”). Under the terms of the agreement, BTG would allow Bioclon to begin selling crotalid antivenom relying on BTG’s 414 patent from October 2018, subject to Bioclon receiving regulatory approval for its antivenom product. BTG will receive a single-digit royalty on sales of any Bioclon product relying on the 414 patent until the end of the exclusivity period in 2028. In addition, Bioclon will withdraw its legal challenge to the validity of the 414 patent. BTG has agreed to reimburse Bioclon USD $6 million for its legal fees and costs incurred. Louise Makin, Chief Executive Officer at BTG, said: “Settling this litigation is good for our business as it removes uncertainty for our investors and other stakeholders. Most importantly, it allows us to concentrate on what we do best, delivering a first-class treatment and supporting our customers and their patients by continuing to invest in a product that has treated over 40,000 people.”
spyder: The Judgement from the Vistoguard case makes very interesting reading if you have the time. There is a lot of information in there suggesting serious questionable management practices, NONE of which reflect well on BTG. I hope someone is able to ask the Board to comment about this at the AGM. It surprises me that the Chairman hasn't taken action yet. hxxps:// Here are just a few direct quotes from the Judge's verdict: Moody also understood that the oncology sales force was too small, and he continued to advocate for more support for Vistogard. In January 2016, BTG fired him. When he ran into some Wellstat executives, Moody confided that he had been fired for “pushing too hard for Vistogard internally.” I find that BTG falsified its model to conceal that its sixteen-person sales force could not provide adequate support for Vistogard. On March 2, 2016, BTG sent Wellstat a seven-year sales forecast. To hide its manipulation of the data, BTG did not send the underlying spreadsheets. BTG only disclosed the annual revenue numbers. BTG claimed that its model forecasted $39.8 million in revenue in the third year and $56 million in revenue in the seventh year. These statements were knowingly and intentionally false. On July 5, 2016, a BTG employee reported that “the existing reps are already very frustrated at their lack of training on Vistogard, and the new ones never had any formal training on Voraxaze. I don’t understand why [BTG management is] unwilling to train the new reps appropriately.”; The answer is that BTG had not supported Vistogard adequately and was trying to cover up its failure to meet its obligations. Wellstat correctly points out that BTG acted aggressively and took disingenuous positions during the litigation. In discovery, BTG refused to produce documents relating to BTG’s strategic shift away from specialty pharmaceuticals or provide a witness pursuant to Court of Chancery Rule 30(b)(6) on the topic, claiming that the subject was not relevant. BTG also objected to Makin being identified as a custodian for documents, claiming that she did not possess relevant information. These positions could not have been asserted in good faith, yet BTG forced Wellstat to prevail on a motion to compel before BTG complied with its discovery obligations. Equally concerning, at trial BTG presented a misleading demonstrative regarding the calculation of Wellstat’s damages.
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210309 02:00:09